Back to search results

Parent-Based Treatment for Adolescent Anxiety

This study is looking at two parent-based approaches to help teenagers (ages 14-17) with anxiety disorders. It compares "Supportive Parenting for Anxious Childhood Emotions" (SPACE) with "Parent Educational Support" (PES). Both involve 12 weekly sessions with parents, which can be in person or online. The study wants to see if SPACE is better at reducing your child's anxiety symptoms and improving family life. To join, your child must have a diagnosed anxiety disorder and stop any other ongoing psychological treatments. The study plans to enroll 108 participants, but its current status is unclear.

Study design
This is a randomized controlled trial, meaning participants are randomly assigned to one of two treatment groups. It involves 108 participants.
What's involved
You would attend 12 weekly sessions with a therapist, either in person or via Zoom. There will be assessments at the beginning, middle, and end of the treatment period.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes at Week 1, Week 7, and Week 14, which includes a post-treatment assessment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07219992

Parent-Based Treatment for Adolescent Anxiety

Recruiting
NAAges 14–17InterventionalTreatment
Yale University
~108 participants
Updated 2025-11-21 on ClinicalTrials.gov
What's tested:Supportive Parenting for Anxious Childhood Emotions (SPACE)Parent Educational Support (PES)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean Pediatric Anxiety Rating Scale (PARS) score
Measured over Week 1 and 14
+3 more outcomes measured

Conditions

Anxiety Disorder of Adolescence

Explore related trials

Anxiety Disorder

NCT07219992

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Yale Child Study Center

    New Haven, Connecticutstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Rebecca Etkin, PhD · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Rebecca Etkin, PhD
[email protected]
203-737-4644
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Meet criteria for a primary DSM-5 AD, including separation anxiety disorder, social anxiety disorder, generalized anxiety disorder, specific phobia, panic disorder, and agoraphobia (determined by the ADIS-C/P).
Cease all other psychosocial treatment, upon consultation with the project staff and service provider.
Not currently use any psychotropic medication, other than a stable dose (i.e., same dose for a minimum of 6 months prior to enrollment; no changes during course of the study) of a stimulant medication or selective serotonin reuptake inhibitor (SSRI).
Have an eligible and willing participating parent (see parent exclusions below).

Exclusion

Meet criteria for any DSM-5 disorder more impairing than the most impairing AD (determined by the ADIS-C/P).
Have any of the following disorders: autism spectrum disorder; intellectual disability; neurocognitive disorders; bipolar disorder; schizophrenia and other psychotic disorders; and alcohol and substance use disorders (determined by the Health History Form and ADIS-C/P).
Report a suicide attempt in the last 3 months, or current suicide intent and plans (determined by the ASQ).
Be a victim of past or present undisclosed abuse requiring investigation or ongoing supervision by the Department of Social Services.
Not have sufficient proficiency with the English language to complete assessments.
Have any of the following: intellectual disability; neurocognitive disorders; untreated bipolar disorder; untreated schizophrenia and other psychotic disorders; and untreated alcohol and substance use disorders (determined by the Health History Form).
Not be living with the adolescent at least 50% of the time for at least one year prior to enrollment.
Not have sufficient proficiency with the English language to complete assessments and treatment.

What this trial measures

  • Mean Pediatric Anxiety Rating Scale (PARS) scoreWeek 1 and 14

    This scale measures anxiety symptoms on 7 dimensions (e.g., avoidance, severity) from 0 ("minimal") to 5 ("extreme"). Total scores range from 0 - 35. Higher scores indicate greater anxiety severity.

  • Mean Screen for Child Anxiety Related Emotional Disorders (SCARED-C/P) scoreWeek 1, 7 and 14

    This scale assesses adolescent anxiety symptoms on a 3-point scale (0 "not true/hardly ever true" to 2 "very true/often true") with total score range = 0 - 82. Higher scores suggest greater anxiety symptoms.

  • Mean Child Anxiety Impact Scale (CAIS-C/P) scoreWeek 1 and 14

    This scale assesses adolescent anxiety that specifically captures impairment related to anxiety across important domains of functioning. Adolescents and parents rate items on a 4-point scale (0 "not at all" to 3 "very much"); total score range = 0 - 81. Higher scores suggest greater anxiety symptoms.

  • Clinical Global Impression Scale - Severity (CGI-S) and Improvement (CGI-I) scales scoreWeek 1 and 14

    This measure will be used to assess overall severity (CGI-S) and improvement (CGI-I) in adolescent anxiety. Total score range for each is 1-7. (Scores of 1 ("very much improved/normal") or 2 ("much improved/borderline ill") indicate a positive treatment response; all other responses are considered negative responses. Higher scores indicate worse outcome.